First Two US Clinical Investigator Sites for AVA6000 Ph 1 Clinical Study Opened

Neil Bell, Chief Development Officer for Avacta Therapeutics, commented: “This timely opening of these two key US sites, under the expert direction of Dr Tap and Professor Cranmer, is a major milestone in Avacta’s entry strategy into the US with our promising AVA6000 pre|CISION™ lead programme. We share with our US colleagues a clear vision to transform treatment outcomes for patients, and we look forward to working together as we continue to build the clinical evidence base for the safety and tolerability of AVA6000, in addition to the significant tumour-targeting potential of the pre|CISION™ platform.”